Véronique Lelong-Boulouard

Prof. Véronique Lelong-Boulouard


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
VLVéronique Lelong-Boulouard
Véronique Lelong-Boulouard
TQThomas Quentin
Thomas Quentin
FMFabien Moreaux
Fabien Moreaux
DDDanièle Debruyne
Danièle Debruyne
MBMichel Boulouard
Michel Boulouard
ACAntoine Coquerel
Antoine Coquerel

12 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BGBlandine de la Gastine
Blandine de la Gastine
SPSoizic Percevault
Soizic Percevault
LVLaurent Varin
Laurent Varin
NRNicolas Richard
Nicolas Richard
FFFabienne Fobe
Fabienne Fobe
VLVéronique Lelong-Boulouard
Véronique Lelong-Boulouard
Cytochrome P450 2D6 (CYP2D6) gene polymorphisms influence the exposure to tramadol (T) and its pharmacologically active metabolite, O-demethyl tramadol (O-dT). Tramadol has been considered as a candidate probe drug for CYP2D6 phenotyping. The objective of the CYTRAM study was to investigate the value of plasma O-dT/T ratio for CYP2D6 phenotyping. European adult patients who received IV tramadol after surgery were included. CYP2D6 genotyping was performed and subjects were classified as extensive (EM), intermediate (IM), poor (PM), or ultra-rapid (UM) CYP2D6 metabolizers. Plasma concentrations of tramadol and O-dT were determined at 24 h and 48 h. The relationship between O-dT/T ratio and CYP2D6 phenotype was examined in both a learning and a validation group. Genotype data were obtained in 301 patients, including 23 PM (8%), 117 IM (39%), 154 EM (51%), and 7 UM (2%). Tramadol trough concentrations at 24 h were available in 297 patients. Mean value of O-dT/T ratio was significantly lower in PM than in non-PM individuals (0.061 ± 0.031 versus 0.178 ± 0.09, p < 0.01). However, large overlap was observed in the distributions of O-dT/T ratio between groups. Statistical models based on O-dT/T ratio failed to identify CYP2D6 phenotype with acceptable sensitivity and specificity. Those results suggest that tramadol is not an adequate probe drug for CYP2D6 phenotyping.

21 August 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
BCBasile Chrétien
Basile Chrétien
SNSophie Nguyen
Sophie Nguyen
CDCharles Dolladille
Charles Dolladille
PMPierre‐Marie Morice
Pierre‐Marie Morice
MHMarie Heraudeau
Marie Heraudeau
VLVéronique Lelong-Boulouard
Véronique Lelong-Boulouard

17 April 2014 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LMLin‐Lin Ma
Lin‐Lin Ma
TFThomas Freret
Thomas Freret
MLMathilde Lange
Mathilde Lange
JBJoanna Bourgine
Joanna Bourgine
ACAntoine Coquerel
Antoine Coquerel
VLVéronique Lelong-Boulouard
Véronique Lelong-Boulouard

4 February 2020 in Trials
Verified
Journal Article
Open access
PDF file
MVMarine Vernant
Marine Vernant
MLMarie Lepoupet
Marie Lepoupet
CCChristian Creveuil
Christian Creveuil
AAAntoine Alix
Antoine Alix
CGCharlotte Gourio
Charlotte Gourio
CGCyril Guillaumé
Cyril Guillaumé
Background: Among palliative care (PC) patients who are administered paracetamol, the subcutaneous (SC) route is often an alternative to the intravenous (IV) route. Yet pharmacological and clinical data on whether these are equivalent pharmacokinetically are lacking. Many French palliative teams are now empirically using paracetamol by the SC route, but there are no data to support this practice. This trial aims to compare the pharmacokinetic (PK) parameters of paracetomol between the IV and SC routes in PC patients. Methods/design: This is a randomized, open, crossover study in two PC centers. The primary endpoints are AUC0-t, AUC0-∞, Cmax, Vd, and t1/2. All adverse events will be reported for a safety analysis. Twenty adult PC patients with an IV device having spontaneous pain not related to care, with a numeric pain rate scale > 3/10, or having a systematic prescription of paracetamol as the usual treatment will be included. All patients also have to meet all eligibility criteria. Conclusion: This is the first study comparing PK parameters for IV paracetamol versus SC paracetamol in PC patients. Trial registration: ClinicalTrials.gov, NCT03944044. Registered on 4 June 2019. Committee for the protection of persons (CPP) 18.09.05.58206 approval 4 October 2018. National Drug Safety Agency (ANSM; Agence Nationale de Sécurité Médicament) MEDAECNAT-2018-09-00009 approval 29 November 2018.

10 December 2024 in European Journal of Pharmacology
Verified
Journal Article
Open access
CCCécile Chofflet
Cécile Chofflet
MHMarie Heraudeau
Marie Heraudeau
PMPierre-Marie Morice
Pierre-Marie Morice
IMImane Mouffok
Imane Mouffok
VLVéronique Lelong-Boulouard
Véronique Lelong-Boulouard
MBMichel Boulouard
Michel Boulouard
Schizophrenia is a chronic mental illness, with a prevalence of about 1%. The symptoms are classified in three categories: positive symptoms, negative symptoms and deficits in cognitive function. Regarding the pharmacological treatment, current antipsychotics mainly improve positive symptoms while negative and cognitive symptoms remain inadequately treated. Among them, aripiprazole, through its pharmacological properties results in regulation of positive symptoms and, to a lesser extent, to negative and cognitive ones. Drug treatment studies in animals typically employ administration methods such as injection or gavage, which is time-consuming over long periods, does not reflect route of administration used in patients, and cause substantial stress in animals. We assessed herein the pharmacokinetic properties and behavioural effects of aripiprazole after chronic administration via drinking solution in C57Bl/6 mice. Results show that subchronic administration of 1 and 10 mg/kg doses of aripiprazole via drinking solution present significant blood concentrations, without any significant effect on the spontaneous activity of mice (between 10 a.m. and 3 p.m.). Furthermore, we described for the first time to our knowledge the main pharmacokinetic parameters of aripiprazole after gavage acute administration (10 mg/kg). Collectively, all of these data will be very useful in future projects including chronic administrations (several months) of this antipsychotic.